JP2025503015A - アルドステロン合成酵素を周期的に抑制することによる高血圧症の治療方法 - Google Patents
アルドステロン合成酵素を周期的に抑制することによる高血圧症の治療方法 Download PDFInfo
- Publication number
- JP2025503015A JP2025503015A JP2024543009A JP2024543009A JP2025503015A JP 2025503015 A JP2025503015 A JP 2025503015A JP 2024543009 A JP2024543009 A JP 2024543009A JP 2024543009 A JP2024543009 A JP 2024543009A JP 2025503015 A JP2025503015 A JP 2025503015A
- Authority
- JP
- Japan
- Prior art keywords
- subject
- beta
- cyp11β2
- serum
- hydroxylase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263300967P | 2022-01-19 | 2022-01-19 | |
| US63/300,967 | 2022-01-19 | ||
| US202263400301P | 2022-08-23 | 2022-08-23 | |
| US63/400,301 | 2022-08-23 | ||
| PCT/IB2023/050444 WO2023139506A1 (en) | 2022-01-19 | 2023-01-19 | Methods of treating hypertension by periodic suppression of aldosterone synthase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503015A true JP2025503015A (ja) | 2025-01-30 |
| JP2025503015A5 JP2025503015A5 (cg-RX-API-DMAC7.html) | 2026-01-26 |
Family
ID=87347916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024543009A Pending JP2025503015A (ja) | 2022-01-19 | 2023-01-19 | アルドステロン合成酵素を周期的に抑制することによる高血圧症の治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250099475A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4466021A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025503015A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240140102A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3240577A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202339758A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023139506A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4577217A4 (en) * | 2022-08-23 | 2026-08-12 | Mineralys Therapeutics Inc | METHODS OF TREATING HYPERTENSION WITH A COMBINATION OF AN ALDOSTERONE SYNTHASE INHIBITOR AND A DIURETIC |
| KR20250053914A (ko) * | 2022-08-23 | 2025-04-22 | 미네랄리스 테라퓨틱스, 아이엔씨. | 비만 대상체에서 고혈압을 치료하는 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9550750B2 (en) * | 2012-10-05 | 2017-01-24 | Merck Sharp & Dohme Corp. | Indoline compounds as aldosterone synthase inhibitors |
| WO2014179186A1 (en) * | 2013-04-30 | 2014-11-06 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
| MY176401A (en) * | 2014-04-24 | 2020-08-05 | Mitsubishi Tanabe Pharma Corp | Novel disubstituted 1,2,4-triazine compound |
| US20240009201A1 (en) * | 2020-10-26 | 2024-01-11 | Mineralys Therapeutics, Inc. | Cyp11b2 beta hydroxylase inhibitors for hypertension |
-
2023
- 2023-01-19 EP EP23743048.3A patent/EP4466021A4/en active Pending
- 2023-01-19 TW TW112102537A patent/TW202339758A/zh unknown
- 2023-01-19 US US18/730,540 patent/US20250099475A1/en active Pending
- 2023-01-19 CA CA3240577A patent/CA3240577A1/en active Pending
- 2023-01-19 WO PCT/IB2023/050444 patent/WO2023139506A1/en not_active Ceased
- 2023-01-19 JP JP2024543009A patent/JP2025503015A/ja active Pending
- 2023-01-19 KR KR1020247027543A patent/KR20240140102A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240140102A (ko) | 2024-09-24 |
| EP4466021A1 (en) | 2024-11-27 |
| WO2023139506A1 (en) | 2023-07-27 |
| CA3240577A1 (en) | 2023-07-27 |
| US20250099475A1 (en) | 2025-03-27 |
| TW202339758A (zh) | 2023-10-16 |
| EP4466021A4 (en) | 2026-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Luther et al. | Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II–induced cardiac, renal, and vascular injury | |
| US9387249B2 (en) | Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone | |
| US9216221B2 (en) | Medicament and method of diagnosis for treating subclinical Cushing's syndrome | |
| JP7814368B2 (ja) | 慢性腎疾患の治療のためのジボテンタン及びダパグリフロジンの組み合わせ | |
| US20250099475A1 (en) | Methods of treating hypertension by periodic suppression of aldosterone synthase | |
| Glicklich et al. | Drug therapy of apparent treatment-resistant hypertension: focus on mineralocorticoid receptor antagonists | |
| Patel et al. | The emerging role of aldosterone synthase inhibitors in overcoming renin–angiotensin–aldosterone system therapy limitations: a narrative review | |
| JP2022075670A (ja) | ネコの全身性疾患の予防又は治療用アンジオテンシンii受容体拮抗薬 | |
| Croom et al. | Eplerenone: a review of its use in essential hypertension | |
| TW201737909A (zh) | 用以腎臟病之治療的醫藥 | |
| US20260053812A1 (en) | Methods of treating hypertension with a combination of an aldosterone synthase inhibitor and a diuretic | |
| US20260053811A1 (en) | Methods of treating hypertension in obese subjects | |
| Elliott et al. | Pharmacology of antihypertensive drugs | |
| Delyani | Anti-aldosterone therapy in the treatment of heart failure: new thoughts on an old hormone | |
| EP1842543A1 (en) | Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist | |
| TW202519234A (zh) | 以洛倫德羅斯塔(lorundrostat)及二或多種降血壓藥物之組合治療高血壓之方法 | |
| EA044411B1 (ru) | Антагонист рецептора ангиотензина ii для предотвращения или лечения системных заболеваний у котов | |
| GB2503396A (en) | Treatment of subclinical Cushing's syndrome and/or incidentaloma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260116 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260116 |